Results 241 to 250 of about 52,122 (312)

Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants. [PDF]

Harm Reduct J
Lasiychuk V, Ghiroli M, López-Castro T, Fox AD.   +3 more
europepmc   +1 more source

Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans

Andrology, Volume 14, Issue 5, Page 1292-1299, July 2026.
ABSTRACT Background Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off‐label treatment.
Shourya Tadisina, Elizabeth Cristiano, Thomas Wiegmann, Ken Grasing, Betty Drees, Ram Sharma, Mariana Garcia‐Touza   +6 more
wiley   +1 more source

Individuals 45 Years and Older in Opioid Agonist Treatment: A Scoping Review. [PDF]

Int J Environ Res Public Health
Gaulen Z, Lunde LH, Alpers SE, Carlsen SL.   +3 more
europepmc   +1 more source

The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Dopaminergic medication used in disorders like Parkinson's disease (PD) and restless legs syndrome can cause impulsive‐compulsive behaviour (ICB), often with strong negative effects on patients' quality of life. This narrative review presents translational evidence on iatrogenic ICB, taking findings from epidemiological, clinical, neuroimaging
Mirjam Wolfschlag, Elena Espa, Kevin Oliveira Hauer, Jonathan Timpka, Ruben Smith, Per Odin, Maria Angela Cenci, Anders Håkansson   +7 more
wiley   +1 more source

Oral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis. [PDF]

BMC Public Health
Bansback N, Tam ACT, Palis H, Kanters S, Popoff E, Schechter MT, Anis AH, Marsh DC, Oviedo-Joekes E.   +8 more
europepmc   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

To smoothie or not to smoothie? A mixed-method approach of nutrition pilot intervention among individuals in opioid agonist treatment. [PDF]

BMC Nutr
Carlsen SL, Furulund E, Arjmand EJ, Fiskaaen KTD, Vold JH, Madebo T, Lid TG, Fadnes LT, ATLAS4LAR and FruktBAR study group.   +8 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Commentary on Young et al.: Clinical guidance is required for stimulant co-prescription with opioid agonist therapy. [PDF]

Addiction
Ezard N, Siefried KJ, Clifford B.
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source